Nonmalignant complications of therapy for Hodgkin's disease

Raymond Hohl, R. L. Schilsky

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Patients successfully treated for Hodgkin's disease provide the oncologist with an opportunity and a responsibility to evaluate long-term adverse effects of staging procedures and treatment regimens. This is necessary both to better understand the often unique clinical problems that develop long after completion of treatment for Hodgkin's disease and to more critically evaluate new treatment programs by comparison with existing effective but toxic regimens. Long-term survivors of Hodgkin's disease have various, often subclinical, cardiac abnormalities that result from both radiation and chemotherapy. Pneumonitis and subsequent fibrosis often follow irradiation. A variety of immunologic disturbances exists before and after treatment and predisposes to significant viral and bacterial infections. Finally, hypothyroidism and premature gonadal failure may follow therapy and require long-term hormone replacement. Further therapeutic advances for Hodgkin's disease will continue to alter this spectrum of complications, which, if unrecognized, may produce significant ongoing morbidity for long-term survivors.

Original languageEnglish (US)
Pages (from-to)331-343
Number of pages13
JournalHematology/Oncology Clinics of North America
Volume3
Issue number2
StatePublished - Jan 1 1989

Fingerprint

Hodgkin Disease
Survivors
Therapeutics
Poisons
Virus Diseases
Hypothyroidism
Bacterial Infections
Pneumonia
Fibrosis
Hormones
Radiation
Morbidity
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{dd46b4cca03f48899a6319f1fd22f756,
title = "Nonmalignant complications of therapy for Hodgkin's disease",
abstract = "Patients successfully treated for Hodgkin's disease provide the oncologist with an opportunity and a responsibility to evaluate long-term adverse effects of staging procedures and treatment regimens. This is necessary both to better understand the often unique clinical problems that develop long after completion of treatment for Hodgkin's disease and to more critically evaluate new treatment programs by comparison with existing effective but toxic regimens. Long-term survivors of Hodgkin's disease have various, often subclinical, cardiac abnormalities that result from both radiation and chemotherapy. Pneumonitis and subsequent fibrosis often follow irradiation. A variety of immunologic disturbances exists before and after treatment and predisposes to significant viral and bacterial infections. Finally, hypothyroidism and premature gonadal failure may follow therapy and require long-term hormone replacement. Further therapeutic advances for Hodgkin's disease will continue to alter this spectrum of complications, which, if unrecognized, may produce significant ongoing morbidity for long-term survivors.",
author = "Raymond Hohl and Schilsky, {R. L.}",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "3",
pages = "331--343",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Nonmalignant complications of therapy for Hodgkin's disease. / Hohl, Raymond; Schilsky, R. L.

In: Hematology/Oncology Clinics of North America, Vol. 3, No. 2, 01.01.1989, p. 331-343.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Nonmalignant complications of therapy for Hodgkin's disease

AU - Hohl, Raymond

AU - Schilsky, R. L.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Patients successfully treated for Hodgkin's disease provide the oncologist with an opportunity and a responsibility to evaluate long-term adverse effects of staging procedures and treatment regimens. This is necessary both to better understand the often unique clinical problems that develop long after completion of treatment for Hodgkin's disease and to more critically evaluate new treatment programs by comparison with existing effective but toxic regimens. Long-term survivors of Hodgkin's disease have various, often subclinical, cardiac abnormalities that result from both radiation and chemotherapy. Pneumonitis and subsequent fibrosis often follow irradiation. A variety of immunologic disturbances exists before and after treatment and predisposes to significant viral and bacterial infections. Finally, hypothyroidism and premature gonadal failure may follow therapy and require long-term hormone replacement. Further therapeutic advances for Hodgkin's disease will continue to alter this spectrum of complications, which, if unrecognized, may produce significant ongoing morbidity for long-term survivors.

AB - Patients successfully treated for Hodgkin's disease provide the oncologist with an opportunity and a responsibility to evaluate long-term adverse effects of staging procedures and treatment regimens. This is necessary both to better understand the often unique clinical problems that develop long after completion of treatment for Hodgkin's disease and to more critically evaluate new treatment programs by comparison with existing effective but toxic regimens. Long-term survivors of Hodgkin's disease have various, often subclinical, cardiac abnormalities that result from both radiation and chemotherapy. Pneumonitis and subsequent fibrosis often follow irradiation. A variety of immunologic disturbances exists before and after treatment and predisposes to significant viral and bacterial infections. Finally, hypothyroidism and premature gonadal failure may follow therapy and require long-term hormone replacement. Further therapeutic advances for Hodgkin's disease will continue to alter this spectrum of complications, which, if unrecognized, may produce significant ongoing morbidity for long-term survivors.

UR - http://www.scopus.com/inward/record.url?scp=0024522061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024522061&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 331

EP - 343

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -